ArriVent BioPharma Inc.
Last updated September 27, 2026
Organization details
- Legal name
- ArriVent BioPharma Inc.
- Ownership
- Public
- Status
- Active
- SIC code
- 2834 — Pharmaceutical Preparations
- Jurisdiction of incorporation
- Delaware
- Headquarters city
- Newtown Square
- Headquarters state / province
- Pennsylvania
- Headquarters country
- United States
- Fiscal year end
- December
- Ticker symbol
- AVBP
- Primary stock exchange
- Nasdaq
Identifiers
- SEC CIK
- 0001868279
Board of directors
-
Bahija Jallal · DirectorSince 2024
- Since 2024
-
Chris Nolet · DirectorSince 2024
- Since 2024
-
John Hohneker · DirectorSince 2024
-
Kristine Peterson · DirectorSince 2024
-
Merdad Parsey · DirectorSince 2025
-
Stuart Lutzker · Director · President of R&DSince 2024
-
Zhengbin Yao · Director · President and CEOSince 2024
Chief executives
Zhengbin Yao
· President and CEO
Since January 2024
Director election results
Annual meeting of June 18, 2026. Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
61.0%
-
94.8%
-
99.7%
Board connections
8 of this board's directors also sit on 20 other boards.
- via Bahija Jallal and Kristine Peterson
- via Carl L. Gordon
- via Zhengbin Yao
- via Merdad Parsey
- via James Healy
- via Carl L. Gordon
- via James Healy
- via Carl L. Gordon
- via John Hohneker
- via Carl L. Gordon
- via Bahija Jallal
- via Kristine Peterson
- via Chris Nolet
- via Carl L. Gordon
- via Carl L. Gordon
- via James Healy
- via James Healy
- via Merdad Parsey
- via Carl L. Gordon
- via James Healy
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $0
- 0 purchases by 0 insiders
- Sold, last 12 months
- $12,983,320
- 1 sale by 1 insider
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Dec 10, 2025 | HHLR ADVISORS, LTD. 10% owner | Open-market sale | −555,555 | $23.37 | $12,983,320 |
| Jul 11, 2025 | LaChapelle Robin Officer (Chief Operating Officer) | Option exercise | +2,050 | $2.28 | $4,674 |
| Jul 11, 2025 | LaChapelle Robin Officer (Chief Operating Officer) | Option exercise | +2,600 | $2.28 | $5,928 |
| Jul 11, 2025 | LaChapelle Robin Officer (Chief Operating Officer) | Option exercise | +6,503 | $2.28 | $14,827 |
| Sep 19, 2024 | LaChapelle Robin Officer (Chief Operating Officer) | Option exercise | +2,700 | $6.24 | $16,848 |
| Sep 19, 2024 | LaChapelle Robin Officer (Chief Operating Officer) | Option exercise | +2,867 | $2.28 | $6,537 |
| Sep 19, 2024 | LaChapelle Robin Officer (Chief Operating Officer) | Option exercise | +7,164 | $2.28 | $16,334 |
| Sep 19, 2024 | LaChapelle Robin Officer (Chief Operating Officer) | Option exercise | +2,471 | $2.28 | $5,634 |
| Sep 19, 2024 | LaChapelle Robin Officer (Chief Operating Officer) | Option exercise | +12,364 | $3.65 | $45,129 |
| Jan 30, 2024 | HHLR ADVISORS, LTD. 10% owner | Derivative conversion | +3,616,041 | — | — |
| Jan 30, 2024 | OrbiMed Asia GP IV, L.P. Director, 10% owner | Derivative conversion | +821,827 | — | — |
| Jan 30, 2024 | Carl L. Gordon Director, 10% owner | Derivative conversion | +821,827 | — | — |
| Jan 30, 2024 | James Healy Director | Derivative conversion | +1,252,308 | — | — |
| Jan 30, 2024 | HHLR ADVISORS, LTD. 10% owner | Derivative conversion | +313,076 | — | — |
| Jan 30, 2024 | OrbiMed Asia GP IV, L.P. Director, 10% owner | Derivative conversion | +821,827 | — | — |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.